Next Generation Therapeutics for the Treatment of Heart Failure and Cardiovascular Diseases
Management and Advisory Team with Extensive Experience in Cardiovascular Science, Medicine and Drug Development
Committed to Transforming the Lives of the Millions of People Living With Heart Disease

Cardiovascular disease is the leading cause of death worldwide in both men and women, accounting for more than 17 million deaths per year, a number that is expected to grow to nearly 24 million by 2030.

Heart failure alone affects more than 6 million people in the U.S. and more than one million patients are admitted to the hospital each year.

Cardurion, a recently launched  Boston-based cardiovascular biotechnology company, is developing novel, next-generation therapeutics for the treatment of heart failure and cardiovascular diseases. Cardurion has locations in both Massachusetts and Japan, surrounded by vibrant academic research institutions that support biotechnology and pharmaceutical companies.
Led by two physician-scientists with extensive experience in cardiovascular science, medicine and drug development, Daniel Bloomfield, M.D. chief executive officer and Michael Mendelsohn, M.D. founder and executive chairman. Cardurion has access to fully-equipped laboratory space, development resources and licenses to a portfolio of preclinical stage cardiovascular drug programs.